I-BASE HIV TREATMENT BULLETINImportant note: Information in this article was accurate in May 2006. The state of the art may have changed since the publication date.
Click here to return to I-BASE main menu
DonateNow

Circumcision: a surprising benefit from an unkind cut

HIV Treat Bull - Vol. 7, No. 5, May 2006


Tom Quinn of Hopkins and the NIAID reviewed the maturing data that show that male circumcision confers protection against HIV infection. The biological basis for the protective effect of circumcision is not clear, but the foreskin is not keratinised and heavily enriched in dendritic cells, making it a potentially advantageous entry site for the virus. Quinn reported a number of epidemiological facts that suggested circumcision protects against HIV infection:

Quinn suggested that as a public health measure safe circumcision should be made available now, and further data developed. In a model of the effect of circumcision, a 50% reduction in relative HIV acquisition risk would cut HIV incidence from 0.8 per 100 person years to 0.4 in women, in addition to the 50% protective effect in men. But if 30% of men believed that sex was now safe and stopped using condoms, the beneficial effect would be abrogated.

The procedure was estimated to cost $69 in Rakai, and therefore would cost 1000 to 3000$ per HIV case prevented. This cost is similar to that of nevirapine prophylaxis for pregnant mothers, in which the cost of an averted infection is estimated to be $2500. Quinn felt that overall circumcision could reduce HIV and STD transmission, reduce cervical cancer, balanitis, and penile cancer. He suggested that preparations be made to offer safe surgery and educate to maintain low-risk behavior.

Ref: Quinn T. Circumcision and HIV transmission: the cutting edge. Plenary lecture Wednesday 8 February, 13th CROI, 2006, Denver. Abstract 120. Webcast available on conference website.

Source: www.natap.org

2008-03-10
IB060705-28


©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.